Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)
-
Narrated by:
-
By:
About this listen
Professor Marc Fisher and Dr Clay Johnston discuss the THALES trial, explaining its rationale, key results and subgroup analyses, and also comment on the potential clinical implications of CHANCE 2.
This programme is made possible thanks to an independent educational grant from AstraZeneca.
Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
What listeners say about Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.